Edition:
India

Celgene Q4 Earnings Per Share $1.50


Thursday, 31 Jan 2019 

Jan 31 (Reuters) - Celgene Corp ::CELGENE REPORTS FOURTH QUARTER AND FULL YEAR 2018 OPERATING AND FINANCIAL RESULTS.Q4 REVENUE $4.037 BILLION VERSUS REFINITIV IBES ESTIMATE OF $3.99 BILLION.Q4 EARNINGS PER SHARE $1.50.Q4 EARNINGS PER SHARE ESTIMATE $2.32 -- REFINITIV IBES DATA.REAFFIRMING 2020 FINANCIAL OUTLOOK.REVLIMID SALES FOR Q4 INCREASED 16 PERCENT TO $2,549 MILLION.OZANIMOD U.S. AND EU REGULATORY SUBMISSIONS ON-TRACK FOR Q1 2019.OTEZLA SALES IN Q4 WERE $448 MILLION, A 21 PERCENT INCREASE YEAR-OVER-YEAR.QTRLY ADJUSTED EARNINGS PER SHARE $2.39.BRISTOL-MYERS SQUIBB AND CELGENE EXPECT TO CLOSE TRANSACTION IN Q3 OF 2019.SEES 2019 GAAP DILUTED EPS $8.40 TO $9.08.2019 GUIDANCE FOR TOTAL REVENUE AND NET PRODUCT SALES OF REVLIMID & OTEZLA UNCHANGED FROM GUIDANCE PROVIDED ON JAN. 7.FY2019 EARNINGS PER SHARE VIEW $10.42, REVENUE VIEW $17.00 BILLION -- REFINITIV IBES DATA.